Introducing a hybrid alternative to Janssen’s Velcade (bortezomib) multiple myeloma and lymphoma treatment in 14 European countries enabled Stada Arzneimittel to record double-digit sales growth for both its Generics operating segment and its group turnover in the first half of this year. “This innovative, ready-to-use solution for injection is one of the most significant product launches in Stada’s history,” the German group stated.
Offering a ready-to-use alternative to the reference brand’s lyophilized powder for injection, Stada launched its value-added formulation of the multiple...






